AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

TALPHERA, INC. Director's Dealing 2014

Mar 11, 2014

35181_dirs_2014-03-11_00ed137a-b6c6-4eda-90a2-87151d9ad6da.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ACELRX PHARMACEUTICALS INC (ACRX)
CIK: 0001427925
Period of Report: 2014-03-02

Reporting Person: Dasu Badri N (Chief Engineering Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2014-03-07	Common Stock	D	1000	$12.4518	Disposed	23910	Direct
2014-03-02	Common Stock	F	1380	$11.43	Disposed	22530	Direct

Footnotes

F1: Balance includes non-reportable acquisition of 6,771 shares of Common Stock through the Company's Employee Stock Purchase Plan.

F2: This is a weighted average sale price. Shares were sold in the range of $12.451-$12.452.

F3: The shares were withheld to satisfy tax liability upon vesting 25% of the restricted stock units of the Company, previously reported on March 4, 2011.